Tag: Cybin Corp - Psychedelic Alpha

Access exclusive insights, data and interviews with Pα+: learn more and subscribe today.

Read more about the article Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Post published:April 21, 2022
Post category:Press Release

Read more about the article Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT

Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT

Post published:April 13, 2022
Post category:Press Release

Read more about the article Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules

Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules

Post published:April 8, 2022
Post category:Press Release

Read more about the article Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

Post published:March 31, 2022
Post category:Press Release

Read more about the article Cybin Announces Additional Adelia Milestone Achievement

Cybin Announces Additional Adelia Milestone Achievement

Post published:March 25, 2022
Post category:Press Release

Read more about the article Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants

Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants

Post published:March 24, 2022
Post category:Press Release

Read more about the article Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights

Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights

Post published:February 10, 2022
Post category:Press Release

Read more about the article Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders

Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders

Post published:February 9, 2022
Post category:Press Release

Read more about the article Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

Post published:January 11, 2022
Post category:Press Release

Read more about the article Cybin Announces Additional Adelia Milestone Achievement

Cybin Announces Additional Adelia Milestone Achievement

Post published:January 6, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.